Arovella Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Arovella Therapeutics şirketinin toplam hissedar öz sermayesi A$11.2M ve toplam borcu A$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$13.3M ve A$2.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	n/a
Nakit	AU$12.71m
Eşitlik	AU$11.23m
Toplam yükümlülükler	AU$2.06m
Toplam varlıklar	AU$13.28m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: E4NA 'nin kısa vadeli varlıkları ( A$13.2M ) kısa vadeli yükümlülüklerini ( A$2.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: E4NA şirketinin kısa vadeli varlıkları ( A$13.2M ) uzun vadeli yükümlülüklerini ( A$15.9K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: E4NA borçsuzdur.

Borcun Azaltılması: E4NA un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: E4NA şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: E4NA serbest nakit akışı her yıl % 14 1.7 yıl yetecek nakit akışına sahip olacaktır.

Arovella Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Arovella Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Arovella Therapeutics Common Shares to Be Deleted from Other OTC

Recent updates

High number of new and inexperienced directors

Arovella Therapeutics Limited Announces Establishment of Clinical Advisory Board

Arovella Therapeutics Limited, Annual General Meeting, Nov 15, 2024

Full year 2024 earnings released: AU$0.009 loss per share (vs AU$0.014 loss in FY 2023)

Arovella Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 12.5 million.

First half 2024 earnings released: AU$0.004 loss per share (vs AU$0.006 loss in 1H 2023)

Arovella Therapeutics Limited Announces Executive Changes

Arovella Therapeutics Limited Announces Changes to its Board

New major risk - Revenue and earnings growth

Forecast to breakeven in 2024

Arovella Therapeutics Limited, Annual General Meeting, Nov 10, 2023

Full year 2023 earnings released: AU$0.014 loss per share (vs AU$0.016 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.008 loss in 1H 2022)

Arovella Therapeutics Ltd Appoints Dr. Nicole Van Der Weerden as Chief Operating Officer, January 4, 2023

High number of new and inexperienced directors

Arovella Therapeutics Limited Announces Europe Patent to Be Granted for Inkt Cell Therapy Platform

Arovella Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Arovella Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Full year 2022 earnings released: AU$0.016 loss per share (vs AU$0.015 loss in FY 2021)

Arovella Therapeutics Ltd Appoints Gary Phillips as an Independent Non-Executive Director

Arovella Therapeutics Limited Announces ZolpiMist Launch Australia

Arovella Therapeutics Ltd Announces Executive Changes

Less than half of directors are independent

Arovella Therapeutics Ltd Announces That the US Patent and Trademark Office Has Accepted Its Patent Application Covering Anagrelide and the Patent Will Proceed to Grant

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Arovella Therapeutics Limited announced that it has received AUD 4.568748 million in funding from Merchant Funds Management Pty Ltd, and other investors

Arovella Therapeutics Limited announced that it expects to receive AUD 4.568748 million in funding from Merchant Funds Management Pty Ltd and other investors

Arovella Therapeutics Common Shares to Be Deleted from Other OTC

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.03 loss in FY 2020)

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.07 loss in FY 2020)

Tony Macintyre and Michael Baker to Assume the Role of Chief Technical Officer of Suda Pharmaceuticals Ltd

Suda Pharmaceuticals Ltd Announces Ordesa Feasibility Study Update

Full year earnings released - €0.07 loss per share

Suda Pharmaceuticals Ltd. Receives the Final Report for a Canine Pharmacokinetic Study

Full year earnings released - €0.07 loss per share

Suda Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.533454 million.

Suda Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.55636 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin